At Atara Biotherapeutics, we firmly believe that the most promising path to finding new therapies comes when those affected by a serious unmet medical need lend their voices to the process. Our company was named and founded for Atara Ciechanover, who, unfortunately, passed away after her battle with ovarian cancer. Taking inspiration from her experience, our mission has been to transform the lives of patients with serious medical conditions. We can only accomplish this mission by connecting with patient champions who are as passionate as we are about finding innovative treatments. Our goals are to educate patients about their disease, develop the safest medicines to treat their disease, and ensure that patients have access to treatment. Please feel free to contact firstname.lastname@example.org with your questions and comments or if you would like to receive updates about our patient advocacy efforts.
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.
Atara’s pipeline includes tab‐cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC).
Post-transplant lymphoproliferative disease (PTLD) is a type of cancer or lymphoma that may occur after bone marrow or organ transplant. A patient who receives a transplant must take medications to suppress their immune system (immunosuppression) so that their body will not reject the new bone marrow or organ. When the immune system is suppressed, it is easier to become sick. Sometimes when a transplant patient is infected with Epstein-Barr virus (EBV), the virus may cause a serious cancer or lymphoma known as PTLD.
If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
We also recognize our clinical studies may not be available to all patients who have life threatening diseases and no satisfactory treatment alternatives. Learn more about Atara’s expanded access programs and compassionate use policy.
The driving force behind everything we do at Atara is to develop treatment options for patients with cancer and other life-threatening diseases. Thanks to the tireless efforts of our medical professionals and our relationships with various research organizations, we are working to make a difference in the lives of patients. Here are some stories of patients who have been diagnosed with PTLD.